Tag: Written Description
-
Federal Circuit Reverses Invalidity Finding for Novartis’ Entresto Patent
On January 10, 2025, the Federal Circuit issued a significant decision in In re Entresto (Sacubitril/Valsartan) Patent Litigation, reversing a district court ruling that had found claims of Novartis’ U.S. Patent 8,101,659 (“the ’659 patent”) invalid for lack of written description. The appellate court affirmed the district court’s rulings that the patent was not invalid…